Form 4 for XENE Xenon Pharmaceuticals Inc.
Accepted 2023-12-15 00:00:00 ET · period of report 2023-12-13 · accession 0000950170-23-070841 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-12-15 | 2023-12-13 | XENE | PATOU GARY | Dir | S - Sale+OE | $39.29 | -11.4K | 23.6K | -33% | -$447.1K |
| DM | 2023-12-15 | 2023-12-13 | XENE | PATOU GARY | Dir | M - OptEx | $9.55 | +14.4K | 30.0K | +93% | +$137.5K |
| DM | 2023-12-15 | 2023-12-13 | XENE | PATOU GARY | Dir | F - Tax | $39.68 | -3,022 | 28.7K | -10% | -$119.9K |
| DI | 2023-12-15 | 2023-12-13 | XENE | PATOU GARY | Dir | S - Sale+OE | $41.05 | -7,598 | 4,902 | -61% | -$311.9K |
| DM | 2023-12-15 | 2023-12-13 | XENE | PATOU GARY | Dir | M - OptEx | $0.00 | -14.3K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2023-12-13 | S | D | 2,303 | $39.10 | 23,573 | D | — | — | (F1) Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period. (F5) The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $39.04 to $39.16, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 2 | Common | Common Shares | 2023-12-13 | M | A | 5,144 | $9.00 | 28,717 | D | — | — | (F1) Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period. |
| 3 | Common | Common Shares | 2023-12-13 | F | D | 1,167 | $39.68 | 27,550 | D | — | — | (F1) Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period. (F3) Represents the closing price of the Company's common shares in U.S. dollars on December 12, 2023, which was converted to a Canadian dollar amount for purposes of net settlement calculations. |
| 4 | Common | Common Shares | 2023-12-13 | S | D | 3,977 | $39.84 | 23,573 | D | — | — | (F1) Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period. |
| 5 | Common | Common Shares | 2023-12-13 | F | D | 577 | $39.68 | 25,876 | D | — | — | (F1) Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period. (F3) Represents the closing price of the Company's common shares in U.S. dollars on December 12, 2023, which was converted to a Canadian dollar amount for purposes of net settlement calculations. |
| 6 | Common | Common Shares | 2023-12-13 | M | A | 2,880 | $9.85 | 26,453 | D | — | — | (F1) Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period. (F2) The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. |
| 7 | Common | Common Shares | 2023-12-13 | S | D | 7,598 | $41.05 | 4,902 | I | — | — | (F1) Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period. (F6) The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.06, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 8 | Common | Common Shares | 2023-12-13 | F | D | 1,278 | $39.68 | 28,673 | D | — | — | (F1) Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period. (F3) Represents the closing price of the Company's common shares in U.S. dollars on December 12, 2023, which was converted to a Canadian dollar amount for purposes of net settlement calculations. |
| 9 | Common | Common Shares | 2023-12-13 | M | A | 6,378 | $9.85 | 29,951 | D See Note | — | — | (F1) Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period. (F2) The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. (F7) By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou. |
| 10 | Common | Common Shares | 2023-12-13 | S | D | 5,100 | $38.94 | 23,573 | D | — | — | (F1) Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period. (F4) The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.81 to $39.13, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 11 | Derivative | Stock Option (Right to Buy) | 2023-12-13 | M | D | 5,144 | $0.00 | 0 | D | $9.00 · 2017-11-04 to 2024-11-03 | 5,144 Common Shares | |
| 12 | Derivative | Stock Option (Right to Buy) | 2023-12-13 | M | D | 2,800 | $0.00 | 0 | D | $9.85 · 2016-12-31 to 2024-01-13 | 2,800 Common Shares | (F2) The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. |
| 13 | Derivative | Stock Option (Right to Buy) | 2023-12-13 | M | D | 6,378 | $0.00 | 0 | D | $9.85 · 2016-12-31 to 2024-01-13 | 6,378 Common Shares | (F2) The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. |